Research Progress of Strengthening Health Qi to Treat Cancer by Regulating Tumor Immunity

TIAN Jianhui

doi:10.3971/j.issn.1000-8578.2021.20.1426

Cancer Research on Prevention and Treatment > 2021 > 48(6): 565-569. > DOI: 10.3971/j.issn.1000-8578.2021.20.1426

TIAN Jianhui. Research Progress of Strengthening Health Qi to Treat Cancer by Regulating Tumor Immunity[J]. Cancer Research on Prevention and Treatment, 2021, 48(6): 565-569. DOI: 10.3971/j.issn.1000-8578.2021.20.1426

Citation:

PDF (3382 KB)

Research Progress of Strengthening Health Qi to Treat Cancer by Regulating Tumor Immunity

TIAN Jianhui^{1, 2}

1.
Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
2.
Cancer Institute of Traditional Chinese Medicine, Shanghai Research Institute of Traditional Chinese Medicine, Shanghai 200032, China

Funding:

National Natural Science Foundation of China 81173224

National Natural Science Foundation of China 81373621

National Natural Science Foundation of China 81774166

National Natural Science Foundation of China 81973517

More Information

Received Date: December 06, 2020
Revised Date: February 23, 2021
Available Online: January 12, 2024

Graphical Abstract

Abstract

Abstract

Traditional Chinese medicine attaches great importance to the health Qi in the prevention and treatment of malignant tumors and emphasizes the concept of "harmonizing yin and yang until a balance is reached". Professor Liu Jiaxiang has established an academic system of "strengthening the health Qi to treat cancer" characterized by "putting people first" and "protecting the health Qi", emphasizing the regulation of the body's internal resistance (including immunity) to prevent and treat malignant tumors. The tumor immunotherapy has been proven effective in the field of pan-cancer and is considered as the most possible cure for cancer. This article deeply studies the scientific connotation of "health Qi" of human body and its role in tumor pathogenesis from the perspective of tumor immunology, which will promote the mutual promotion and integration of traditional Chinese medicine and oncology, and further improve the efficiency of prevention and control of malignant tumors in China through the integration of traditional Chinese and Western medicine.
- Strengthening the health Qi to treat cancer,
- Tumor immunology,
- Health Qi,
- Immune editing,
- Hidden toxicity due to health qi deficiency

FullText(HTML)

Competing interests: The authors declare that they have no competing interests.

References (43)

References

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7-30. doi: 10.3322/caac.21590
[2]	Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments[J]. Lancet, 2017, 389(10066): 299-311. doi: 10.1016/S0140-6736(16)30958-8
[3]	Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019[J]. CA Cancer J Clin, 2019, 69(5): 363-385. doi: 10.3322/caac.21565
[4]	Salles G, Barrett M, Foà R, et al. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience[J]. Adv Ther, 2017, 34(10): 2232-2273. doi: 10.1007/s12325-017-0612-x
[5]	da Cunha Santos G, Shepherd FA, Tsao MS. EGFR mutations and lung cancer[J]. Annu Rev Pathol, 2011, 6: 49-69. doi: 10.1146/annurev-pathol-011110-130206
[6]	Gharwan H, Groninger H. Kinase inhibitors and monoclonal antibodies in oncology: clinical implications[J]. Nat Rev Clin Oncol, 2016, 13(4): 209-227. doi: 10.1038/nrclinonc.2015.213
[7]	Hegde PS, Chen DS. Top 10 Challenges in Cancer Immunotherapy[J]. Immunity, 2020, 52(1): 17-35. doi: 10.1016/j.immuni.2019.12.011
[8]	田建辉. 中西医融合提高肿瘤综合治疗疗效的思考[J]. 中国中西医结合杂志, 2017, 37(9): 1032-1033. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ201709002.htm Tian JH. Thinking on improving the effect of comprehensive treatment of tumor by fusing traditional Chinese medicine and Western medicine[J]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2017, 37(9): 1032-1033. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ201709002.htm
[9]	刘嘉湘. 扶正治癌融汇中西继承创新[J]. 中国中西医结合杂志, 2019, 39(1): 10-12. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ201901003.htm Liu JX. Treating Cancer by Strengthening Vital Qi-A Inherited and Inovative Method with Integrating Chinese and Western Medicine[J]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2019, 39(1): 10-12. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ201901003.htm
[10]	中国科学技术协会. 2020重大科学问题和工程技术难题发布[N]. 科技日报, 2020-08-17(1). China Association for Science and Technology. 2020: Major Scientific Issues and engineering challenges released[N]. Science and Technology Daily, 2020-08-17(1).
[11]	Schipper H. Treating cancer: is kill cure?[J]. Ann Acad Med Singap, 1994, 23(3): 382-386. http://www.ncbi.nlm.nih.gov/pubmed/7944255
[12]	Gatenby RA. A change of strategy in the war on cancer[J]. Nature, 2009, 459(7246): 508-509. doi: 10.1038/459508a
[13]	田建辉, 席志超, 罗斌, 等. "扶正治癌"理论的科学内涵[J]. 世界科学技术-中医药现代化, 2019, 21(5): 943-948. https://www.cnki.com.cn/Article/CJFDTOTAL-SJKX201905018.htm Tian JH, Xi ZC, Luo B, et al. Scientific connotation of the Theory of "Strengthening Vital Qi to Treat Cancer"[J]. Shi Jie Ke Xue Ji Shu-Zhong Yi Yao Xian Dai Hua, 2019, 21(5): 943-948. https://www.cnki.com.cn/Article/CJFDTOTAL-SJKX201905018.htm
[14]	田建辉. 以人为本刘嘉湘"扶正治癌"学术思想之"道"[N]. 中国中医药报, 2017-01-11(4). Tian JH. The "Tao" of Liu jia-xiang academy of "Strengthening Vital Qi to Treat Cancer" based on people oriented theroy[N]. China News of Traditional Chinese Medicine, 2017-01-11(4).
[15]	田建辉. 调护正气刘嘉湘"扶正治癌"之根本大法[N]. 中国中医药报, 2017-01-13(4). Tian JH. The Fundamental treatment of Liu jia-xiang academy of "Strengthening Vital Qi to Treat Cancer" based on regulating Healthy Qi[N]. China News of Traditional Chinese Medicine, 2017-01-13(4).
[16]	田建辉. 刘嘉湘"扶正治癌"思想之"术"[N]. 中国中医药报, 2017-01-19. Tian JH. The "skills" of Liu jia-xiang academy of "Strengthening Vital Qi to Treat Cancer"[N]. China News of Traditional Chinese Medicine, 2017-01-19.
[17]	田建辉. 刘嘉湘"扶正治癌"学术思想的先进性[N]. 中国中医药报, 2017-01-26. Tian JH. The advanced nature of Liu jia-xiang academy of "Strengthening Vital Qi to Treat Cancer"[N]. China News of Traditional Chinese Medicine, 2017-01-26.
[18]	Sanmamed MF, Chen L. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization[J]. Cell, 2018, 175(2): 313-326. doi: 10.1016/j.cell.2018.09.035
[19]	刘嘉湘. 中医药治疗肺癌研究思路和临床经验[J]. 世界中医药, 2007, 2(2): 67-70. doi: 10.3969/j.issn.1673-7202.2007.02.001 Liu JX. Research thought and clinical experience in treatment of lung cancer with chinese medicine[J]. Shi Jie Zhong Yi Yao, 2007, 2(2): 67-70. doi: 10.3969/j.issn.1673-7202.2007.02.001
[20]	刘嘉湘, 田建辉. 传承中医药学术精华, 促进肿瘤学创新发展[J]. 上海中医药杂志, 2020, 54(7): 29-33. https://www.cnki.com.cn/Article/CJFDTOTAL-SHZZ202007008.htm Liu JX, Tian JH. Promoting innovation and development of oncology by inheriting TCM academic essence[J]. Shanghai Zhong Yi Yao Za Zhi, 2020, 54(7): 29-33. https://www.cnki.com.cn/Article/CJFDTOTAL-SHZZ202007008.htm
[21]	田建辉. "正虚伏毒"为肺癌发病的核心病机[J]. 上海中医药杂志, 2016, 50(12): 10-14. https://www.cnki.com.cn/Article/CJFDTOTAL-SHZZ201612003.htm Tian JH. Discussion on the pathogenesis of lung cancer with "deficiency of vital qi and hidden toxin"[J]. Shanghai Zhong Yi Yao Za Zhi, 2016, 50(12): 10-14. https://www.cnki.com.cn/Article/CJFDTOTAL-SHZZ201612003.htm
[22]	罗斌, 阙祖俊, 姚嘉良, 等. 人非小细胞肺癌循环肿瘤细胞系的建立及意义——肺癌转移病因"伏毒"的本质研究[J]. 世界科学技术-中医药现代化, 2019, 21(5): 983-987. https://www.cnki.com.cn/Article/CJFDTOTAL-SJKX201905024.htm Luo B, Que ZJ, Yao JL, et al. Establishment and Significance of Circulating Tumor Cell Line in Human Non-small Cell Lung Cancer——Study on the Essence of "Hidden Poison" in Metastasis of Lung Cancer[J]. Shi Jie Ke Xue Ji Shu-Zhong Yi Yao Xian Dai Hua, 2019, 21(5): 983-987. https://www.cnki.com.cn/Article/CJFDTOTAL-SJKX201905024.htm
[23]	衣秀秀, 罗斌, 钱芳芳, 等. 从免疫抑制和循环肿瘤细胞探讨肺癌核心病机"正虚伏毒"的生物学基础[J]. 世界科学技术-中医药现代化, 2019, 21(5): 963-969. https://www.cnki.com.cn/Article/CJFDTOTAL-SJKX201905021.htm Yi XX, Luo B, Qian FF, et al. Exploring the Biological Basis of Lung Cancer Core Pathogenesis"Declined Healthy Qi and Hidden Toxin"from the Perspective of Immune Disorders and Circulating Tumor Cell[J]. Shi Jie Ke Xue Ji Shu-Zhong Yi Yao Xian Dai Hua, 2019, 21(5): 963-969. https://www.cnki.com.cn/Article/CJFDTOTAL-SJKX201905021.htm
[24]	阙祖俊, 罗斌, 董昌盛, 等. "正虚伏毒"肺癌研究平台的构建[J]. 上海中医药杂志, 2019, 53(4): 11-16. https://www.cnki.com.cn/Article/CJFDTOTAL-SHZZ201904004.htm Que ZJ, Luo B, Dong CS, et al. Construction of lung cancer research platform under the theory of "hidden toxicity due to vital qi deficiency"[J]. Shanghai Zhong Yi Yao Za Zhi, 2019, 53(4): 11-16. https://www.cnki.com.cn/Article/CJFDTOTAL-SHZZ201904004.htm
[25]	田建辉, 刘海涛, 董昌盛, 等. 御神在肿瘤防治中的作用探析[J]. 中医杂志, 2018, 59(24): 2093-2098. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYZ201824006.htm Tian JH, Liu HT, Dong CS, et al. Discussion on Defending Spirit in Cancer Prevention and Treatment[J]. Zhong Yi Za Zhi, 2018, 59(24): 2093-2098. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYZ201824006.htm
[26]	封佳莉, 李和根, 周晓辉, 等. 中医药干预874例晚期非小细胞肺癌的生存分析[J]. 安徽中医药大学学报, 2019, 38(6): 10-15. doi: 10.3969/j.issn.2095-7246.2019.06.004 Feng JL, Li HG, Zhou XH, et al. Survival of Patients with Advanced Non-small Cell Lung Cancer After Traditional Chinese Medicine Intervention: An Analysis of 874 Cases[J]. Anhui Zhong Yi Yao Da Xue Xue Bao, 2019, 38(6): 10-15. doi: 10.3969/j.issn.2095-7246.2019.06.004
[27]	朱惠蓉, 刘嘉湘. 益肺抗瘤饮对Lewis肺癌荷瘤小鼠神经内分泌免疫的实验研究[J]. 上海中医药大学学报, 2000, 14(2): 44-46. https://www.cnki.com.cn/Article/CJFDTOTAL-SHZD200002015.htm Zhu HR, Liu JX. Experimental study of "Lung-Benefiting and Tumor-Resisting Drink" on neuroendocrine immunity in mice with lewis pulmonary cancer[J]. Shanghai Zhong Yi Yao Da Xue Xue Bao, 2000, 14(2): 44-46. https://www.cnki.com.cn/Article/CJFDTOTAL-SHZD200002015.htm
[28]	罗斌, 阙祖俊, 朱丽华, 等. 非小细胞肺癌患者外周血CD11b~+CD33~+CD15~+CD14~-及CD11b~+CD33~+CD15~-CD14~+髓系细胞的比例变化及临床意义[J]. 现代免疫学, 2017, 37(1): 25-31. https://www.cnki.com.cn/Article/CJFDTOTAL-SHMY201701005.htm Luo B, Que ZJ, Zhu LH, et al. The expression of myeloid-derived suppressor cells in the peripheral blood of patients with NSCLC and its clinical significance[J]. Xian Dai Mian Yi Xue, 2017, 37(1): 25-31. https://www.cnki.com.cn/Article/CJFDTOTAL-SHMY201701005.htm
[29]	许荣忠, 方志红, 吴建春, 等. 中医药不同治则对非小细胞肺外周血免疫指标影响的临床研究[J]. 辽宁中医杂志, 2020, 47(11): 87-91. https://www.cnki.com.cn/Article/CJFDTOTAL-LNZY202011027.htm Xu RZ, Fang ZH, Wu JC, et al. Clinical Study on Effect of Different Therapeutic Principles of Traditional Chinese Medicine on Immune Indicators of Non-small Cell Pulmonary Peripheral Blood[J]. Liaoning Zhong Yi Za Zhi, 2020, 47(11): 87-91. https://www.cnki.com.cn/Article/CJFDTOTAL-LNZY202011027.htm
[30]	梁玉杰, 段永强, 成映霞, 等. 衰老进程中机体免疫器官和免疫细胞因子变化及健脾补肾中药的干预研究[J]. 中国中医药信息杂志, 2012, 19(3): 42-44. doi: 10.3969/j.issn.1005-5304.2012.03.016 Liang YJ, Duan YQ, Cheng YX, et al. Variation of Immune Organs and Immune Cytokines of Aging and Intervention of Chinese Medicine with Spleen-strengthening and Kidney-tonifying[J]. Zhongguo Zhong Yi Yao Xin Xi Za Zhi, 2012, 19(3): 42-44. doi: 10.3969/j.issn.1005-5304.2012.03.016
[31]	田建辉, 杨晓霞, 毕凌, 等. 金复康口服液对免疫衰老小鼠肺癌移植瘤的防治作用[J]. 中国肿瘤生物治疗杂志, 2016, 23(1): 36-43. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLSW201601009.htm Tian JH, Yang XX, Bi L, et al. Effect of Jinfukang decoction on prevention and treatment of transplanted lung cancer in immunosenescence mouse model[J]. Zhongguo Zhong Liu Sheng Wu Zhi Liao Za Zhi, 2016, 23(1): 36-43. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLSW201601009.htm
[32]	毕凌, 金莎, 郑展, 等. 肺积方对IDO诱导Lewis肺癌小鼠模型免疫逃逸的影响[J]. 中国中西医结合杂志, 2016, 36(1): 69-74. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ201601022.htm Bi L, Jin S, Zheng Z, et al. Inhibitory Effect of Feiji Recipe on IDO Induced Immune Escape on the Murine Model of Lewis Lung Carcinoma[J]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2016, 36(1): 69-74. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ201601022.htm
[33]	张盈盈, 齐元富, 谭鹏程. 芪贞固本方对Lewis肺癌小鼠肿瘤生长及免疫器官的影响[J]. 山东中医杂志, 2016, 35(7): 637-640. https://www.cnki.com.cn/Article/CJFDTOTAL-SDZY201607022.htm Zhang YY, Qi YF, Tan PC. Effects of Qizhen Guben Formula on Tumor Growth and Immune Organ in Lewis Lung Carcinoma Mice[J]. Shangdong Zhong Yi Za Zhi, 2016, 35(7): 637-640. https://www.cnki.com.cn/Article/CJFDTOTAL-SDZY201607022.htm
[34]	阎学伟, 龚陈媛, 祝晓雯, 等. 玫瑰树碱促进NK细胞识别与杀伤非小细胞肺癌细胞的研究[J]. 中国药理学通报, 2020, 36(9): 1240-1247. doi: 10.3969/j.issn.1001-1978.2020.09.011 Yan XW, Gong CY, Zhu XW, et al. Research on ellipticine promoting NK cells to recognize and kill non-small cell lung cancer cells[J]. Zhongguo Yao Li Xue Tong Bao, 2020, 36(9): 1240-1247. doi: 10.3969/j.issn.1001-1978.2020.09.011
[35]	徐蔚杰, 刘嘉湘, 赵丽红, 等. 益气养阴解毒方对晚期非小细胞肺癌相关免疫指标及血清sB7-H3的影响[J]. 上海中医药杂志, 2017, 51(4): 53-56. https://www.cnki.com.cn/Article/CJFDTOTAL-SHZZ201704014.htm Xu WJ, Liu JX, Zhao LH, et al. Effects of Yiqi Yangyin Jiedu Formula on advanced non-small cell lung cancer related immune indexes and serum sB7-H3[J]. Shanghai Zhong Yi Yao Za Zhi, 2017, 51(4): 53-56. https://www.cnki.com.cn/Article/CJFDTOTAL-SHZZ201704014.htm
[36]	贾程辉, 李枋霏, 何莉莎, 等. 扶正解毒方对前胃癌荷瘤小鼠术后复发模型肿瘤相关巨噬细胞及相关细胞因子的干预研究[J]. 中国中医基础医学杂志, 2014, 20(6): 748-751. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJC201406015.htm Jia CH, Li FF, He LS, et al. The Effect of Fuzheng Jiedu Formula on Tumor Associated Macrophage and Related Cytokine in the Mouse Gastric Cancer Postoperative Recurrence Model[J]. Zhongguo Zhong Yi Ji Chu Yi Xue Za Zhi, 2014, 20(6): 748-751. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJC201406015.htm
[37]	张朋, 刘苓霜, 姜怡, 等. 病证结合的中医药维持治疗方案干预晚期非小细胞肺癌免疫逃逸的临床研究[J]. 中华中医药杂志, 2018, 33(11): 5234-5239. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201811123.htm Zhang M, Liu LS, Jiang Y, et al. Clinical study on the intervention of advanced NSCLC immuneescape with traditional Chinese medicine maintenance therapy of combination of diseases and syndrome[J]. Zhonghua Zhong Yi Yao Za Zhi, 2018, 33(11): 5234-5239. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201811123.htm
[38]	李枋霏, 李杰. 扶正培本法治疗恶性肿瘤作用机制的研究进展[J]. 肿瘤防治研究, 2014, 41(6): 674-679. doi: 10.3971/j.issn.1000-8578.2014.06.037 Li FF, Li J. Mechanism of Fuzheng Peiben Therapy in Treating Malignant Tumor[J]. Zhong Liu Fang Zhi Yan Jiu, 2014, 41(6): 674-679. doi: 10.3971/j.issn.1000-8578.2014.06.037
[39]	孙钢, 刘嘉湘, 李培成. 益肺抗瘤饮对肺癌患者Th1/Th2作用的研究[J]. 辽宁中医杂志, 2001, 28(12): 733-734. doi: 10.3969/j.issn.1000-1719.2001.12.017 Sun G, Liu JX, Li PC. Research on Effect of "Yifeikangliuyin" on Th1 and Th2 in Patients with Lung Cancer[J]. Liaoning Zhong Yi Za Zhi, 2001, 28(12): 733-734. doi: 10.3969/j.issn.1000-1719.2001.12.017
[40]	Li P, Lu M, Shi J, et al. Dual roles of neutrophils in metastatic colonization are governed by the host NK cell status[J]. Nat Commun, 2020, 11(1): 4387. doi: 10.1038/s41467-020-18125-0
[41]	Chockley PJ, Chen J, Chen G, et al. Epithelial-mesenchymal transition leads to NK cell-mediated metastasis-specific immunosurveillance in lung cancer[J]. J Clin Invest, 2018, 128(4): 1384-1396. doi: 10.1172/JCI97611
[42]	Michaudel C, Sokol H. The Gut Microbiota at the Service of Immunometabolism[J]. Cell Metab, 2020, 32(4): 514-523. http://www.sciencedirect.com/science/article/pii/S1550413120304824
[43]	Wang Y, Zhang Q, Chen Y, et al. Antitumor effects of immunity-enhancing traditional Chinese medicine[J]. Biomed Pharmacother, 2020, 121: 109570. http://www.ncbi.nlm.nih.gov/pubmed/31710893

[1]	CHEN Yufan, LI Sicong, CUI Yiyuan, FENG Li. Research Progress of Fuzheng Jiedu Huayu Method in Reducing Toxicity and Enhancing Efficacy of Immunotherapy[J]. Cancer Research on Prevention and Treatment, 2025, 52(1): 11-18. DOI: 10.3971/j.issn.1000-8578.2025.24.0839
[2]	Innovative "Toxicity Attenuation" Technology by the Chinese Team Will Benefit 99% of NPC Patients, etc[J]. Cancer Research on Prevention and Treatment, 2023, 50(3): 326-326. DOI: 10.3971/j.issn.1000-8578.2023.03.0001
[3]	LYU LYU, LIN Jie. Immunoediting-induced Immunotherapy Resistance[J]. Cancer Research on Prevention and Treatment, 2020, 47(4): 243-250. DOI: 10.3971/j.issn.1000-8578.2020.19.1363
[4]	LI Yang, YANG Lingling, BAI Yanli, MING Haixia. Effects of Astragalus Polysaccharides on Growth, Metastasis and Cell Cycle of Lewis Lung Cancer in Tumor-bearing Mice with Qi and Yin Deficiency[J]. Cancer Research on Prevention and Treatment, 2018, 45(3): 131-137. DOI: 10.3971/j.issn.1000-8578.2018.17.0220
[5]	WU Youjun, DU Xiaohui. Role of Adenosine 2a Receptor in Promoting Immune-suppressive Status in Tumor Microenvironment[J]. Cancer Research on Prevention and Treatment, 2017, 44(6): 433-436. DOI: 10.3971/j.issn.1000-8578.2017.16.1400
[6]	GAN Ning, CHEN Huan chao. Effective Observation of Huang -qi Injection Assisted with Chemotherapy for Treatment of Elderly Patients with Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2004, 31(07): 433-434. DOI: 10.3971/j.issn.1000-8578.257
[7]	LI Ming-song, YUAN Aai-li, CHENG Chun-Long, . Dendritic Cell Induce Efficient and Specific Antitumor Immunity[J]. Cancer Research on Prevention and Treatment, 2000, 27(02): 175-176. DOI: 10.3971/j.issn.1000-8578.1677
[8]	Liu Hua, . The Effects of Shengmaisan on the Reduction of Chemotherapy-Induced Toxicities[J]. Cancer Research on Prevention and Treatment, 1998, 25(5): 404-405.
[9]	THE SERUM LIPOPEROXIDE LEVEL IN NORMAL HEALTH AND SOME PATIENTS WITH MALIGNANCIES[J]. Cancer Research on Prevention and Treatment, 1989, 16(4): 242-243,223.
[10]	Cao Kai, . THE SERUM LIPOPEROXIDE LEVEL IN NORMAL HEALTH AND SOME PATIENTS WITH MALIGNANCIES[J]. Cancer Research on Prevention and Treatment, 1989, 16(4): 221-223.

Cited By

Get Citation

PDF

XML

Article views (1638) PDF downloads (330)

Turn off MathJax

Article Contents

Abstract

References

Research Progress of Strengthening Health Qi to Treat Cancer by Regulating Tumor Immunity

Abstract

References

Related Articles

Catalog

Download Center

Links

Contact Us

Research Progress of Strengthening Health Qi to Treat Cancer by Regulating Tumor Immunity

Abstract

References

Related Articles

Catalog

Download Center

Links

Contact Us

Export File

Citation

Format

Content